Michael S. Gordon, MD, Named Medical Director for Virginia G. Piper
Cancer Center Clinical Trials at Scottsdale Healthcare

Get Permission

Michael S. Gordon, MD

Michael S. Gordon, MD, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare in Phoenix. Dr. Gordon will oversee the center’s phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen, is a leading clinical research site for phase I investigations of new anticancer agents.

Dr. Gordon, a Medical Oncologist, currently serves as CEO of Pinnacle Oncology Hematology, a division of Arizona Center for Cancer Care, in ­Scottsdale, focusing on translational research and the care and management of cancer patients seeking phase I and phase II clinical trials. He is a Clinical Professor of Internal Medicine at the University of Arizona College of Medicine in ­Phoenix, and he is actively engaged in the education of medical students as Co-Director of the
Oncology Block.

Dr. Gordon’s principal research interests are in development of new cancer therapies with a focus on targeted and immunologic therapies as well as drugs that affect angiogenesis. Bevacizumab (Avastin), pertuzumab (Perjeta), and oprelvekin (Neumega) are among the drugs Dr. Gordon has helped validate for FDA approval. His area of disease focuses include kidney cancer, melanoma, prostate cancer, lung cancer, gastrointestinal stromal tumor (GIST), and ovarian cancer.

Commitment to Patients and Community

“The care and management of patients with cancer and associated diagnoses is rapidly evolving. The ability to provide patients with cutting-edge treatments has the potential to transform the way cancer care is delivered. The Virginia G. Piper Cancer Center at Scottsdale Healthcare has always been a leader in this regard, and its relationships with its community partners defines Scottsdale Healthcare’s commitment to our patients and our community,” said Dr. Gordon.

“I look forward to working with my colleagues and to the evolution of a new dynamic as we work to accelerate the access to new cancer drugs to our patients in need. By focusing on innovation in a collaborative spirit with our community physicians, we reinforce our primary commitment to our patients and their families,” he continued. ■